VEGFA and hepatocellular carcinoma: Based on these discoveries, anti-angiogenesis therapies including drugs targeting VEGF, such as sorafenib, has been approved to be used as the first systemic therapy of HCC, marking a major milestone in the treatment of advanced HCC.